The gut microbiota and metabolite profiles are altered in patients with spinal cord injuryOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked how the gut microbiota and circulating metabolites change after spinal cord injury (SCI), and whether they are linked. Researchers combined 16S rRNA gene sequencing of stool with untargeted serum metabolomics. Beta diversity was assessed with PCoA, PLS-DA, and ANOSIM. Differential taxa were identified with LEfSe analysis. Serum metabolites were profiled by liquid chromatography-mass spectrometry. Spearman correlation linked microbiota, metabolites, and clinical parameters, including injury duration and ASIA neurological grade.
Who was studied?
The cohort was 21 people from Guangdong Province, China: 11 patients with cervical or thoracic spinal cord injury and 10 matched healthy controls. All were aged 14 years or older. SCI patients had neurological function graded A to D on the ASIA Impairment Scale. Groups were matched for age and gender and shared similar diets. Patients with cauda equina injury, infection, diabetes, tumor, or recent antibiotic or probiotic use were excluded. Standard dietary guidance was given for three days before sampling.
What were the most important findings?
Beta diversity separated SCI patients from controls, confirming dysbiosis. At the genus level, Enterococcus and UBA1819 were significantly enriched in SCI, while Faecalibacterium, Blautia, Escherichia-Shigella, and others were depleted. LEfSe identified 68 differential components, 20 enriched in SCI and 48 in controls. Serum metabolomics found 41 named differential metabolites, 18 up and 23 down. UBA1819 correlated positively with serum uridine (p equals 0.004). Metabolites were enriched in histidine metabolism and FoxO signaling pathways. Neurological grade and injury duration correlated with specific taxa and with kojic acid and deoxycholic acid.
What are the greatest implications of this study?
The results suggest gut dysbiosis after spinal cord injury is tied to systemic metabolic disturbance and injury severity. The authors propose uridine, hypoxanthine, PC(18:2/0:0), and kojic acid as candidate therapeutic targets. UBA1819, which rose after SCI, correlated with uridine and with worse motor function, hinting at a role in inflammation and nerve repair. The study was small (11 patients) and cross-sectional, without validation of the differential taxa or metabolites. Correlations cannot establish that microbiota changes cause SCI outcomes rather than reflecting them.